SynthesisNeurosurgical review2021
Repeat stereotactic radiosurgery for progressive vestibular schwannomas after previous radiosurgery: a systematic review and meta-analysis.
Synthesis in Neurosurgical review, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Machine learning-based models in prediction of the radiological outcomes of vestibular schwannoma following stereotactic radiosurgery: a systematic review and meta-analysis.BMC neurology · 2025Pooled it
- Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2: a systematic review and meta-analysis.BMC cancer · 2025Pooled it
- Salvage microsurgery for vestibular schwannoma after failed stereotactic radiosurgery: a multi-institutional retrospective study.Journal of neuro-oncology · 2026Article
- Birds on a wire: Gamma Knife radiosurgery for two schwannomas along the same cranial nerve. Illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Reirradiation with stereotactic radiosurgery for vestibular schwannomas - a systematic review and meta-analysis.Clinical and translational radiation oncology · 2025Review
- Fractionated Gyroscopic Radiosurgery for Optic Nerve Glioma: A Case Report and Review of the Literature.Cureus · 2025Article
- Clinical Outcomes of Salvage Microsurgical Resection after Radiation Therapy for Sporadic Vestibular Schwannomas.Journal of neurological surgery. Part B, Skull base · 2025Article
- Dynamics of tumor evolution after Gamma Knife radiosurgery for sporadic vestibular schwannoma: Defining volumetric patterns characterizing individual trajectory.Neuro-oncology · 2025Article
- Repeat stereotactic radiosurgery for progressive vestibular schwannomas after primary gamma knife radiosurgery.Journal of neuro-oncology · 2024Article
- Adaptive treatment strategy for a vestibular schwannoma in a patient with vascular Eagle syndrome: illustrative case.Journal of neurosurgery. Case lessons · 2024Article
- Stereotactic radiosurgery for the treatment of hypoglossal schwannoma: a multi-institutional retrospective study.Acta neurochirurgica · 2022Article
- Stereotactic radiosurgery for hypoglossal schwannoma.BMJ case reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Vestibular schwannomas (VS) are slow-growing intracranial extraaxial benign tumors, developing from the vestibular part of the eight cranial nerves. Stereotactic radiosurgery (SRS) has now a long-term scientific track record as first intention treatment for small- to medium-sized VS. Though its success rate is very high, SRS for VS might fail to control tumor growth in some cases. However, the literature on repeat SRS after previously failed SRS remains scarce and reported in a low number of series with a limited number of cases. Here, we aimed at performing a systematic review and meta-analysis of the literature on repeat SRS for VS. Using PRISMA guidelines, we reviewed manuscripts published between January 1990 and October 2020 and referenced in PubMed. Tumor control and cranial nerve outcomes were evaluated with separate meta-analyses. Eight studies comprising 194 patients were included. The overall rate of patients treated in repeat SRS series as per overall series with first SRS was 2.2% (range 1.2-3.2%, p < 0.001). The mean time between first and second SRS was 50.7 months (median 51, range 44-64). The median marginal dose prescribed at first SRS was 12 Gy (range 8-24) and at second SRS was 12 Gy (range 9.8-19). After repeat SRS, tumor stability was reported in 61/194 patients, i.e., a rate of 29.6% (range 20.2-39%, I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.